Central sleep apnoea with ticagrelor
- PDF / 171,611 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 105 Downloads / 221 Views
1
Central sleep apnoea with ticagrelor There may be a link between the use of ticagrelor [Brilinta] and central sleep apnoea (CSA), according to a Summary Safety Review published by Health Canada. Brilinta is available in Canada as 60mg or 90mg tablets; about 2 million prescriptions were filled in 2014–2019. The publication of two confirmed CSA cases in the British Journal of Clinical Pharmacology triggered the review. Two cases of CSA have been reported in Canada; however, neither had enough information to be assessed. Searching of literature and databases revealed 9 international case reports; one was not likely to be linked to Brilinta. Of the remaining cases, 4 were probably linked to Brilinta and 4 were possibly linked. Although there were published results from two studies, both had design weaknesses and the results were conflicting, and there was not enough information to establish a link with Brilinta. The Health Canada review concluded that there may be a risk of CSA with Brilinta, and has requested an update of the Canadian product safety information from the manufacturer. The agency will continue to monitor adverse events, and encourages healthcare providers and patients to report and adverse events. Health Canada. Summary Safety Review - Brilinta (ticagrelor) - Health Canada. Internet Document : 28 Oct 2020. Available from: URL: https://hpr-rps.hres.ca/reg-content/ 803515034 summary-safety-review-detail.php?lang=en&linkID=SSR00248
»
Editorial comment: Details of the two case reports triggering the review have previously been published [see Reactions 1765 p270; 803411781].
0114-9954/20/1830-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 14 Nov 2020 No. 1830
Data Loading...
